NasdaqCM:NEOHealthcare
Assessing NeoGenomics (NEO) Valuation After Earnings Growth, Wider Annual Loss And New Guidance
Why NeoGenomics (NEO) is back on investors’ radar
NeoGenomics (NEO) recently released fourth quarter and full year 2025 results alongside fresh 2026 guidance, combining revenue growth, a smaller quarterly loss, and a wider full year loss that gives investors more financial clarity.
See our latest analysis for NeoGenomics.
NeoGenomics’ recent earnings release and 2026 guidance came after a weaker stretch for the stock, with a 30 day share price return of 22.17% and a 1 year total shareholder...